Jones D - Search Results

1

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.

Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. Rogers KA, et al. Among authors: jones d. Haematologica. 2021 Sep 1;106(9):2364-2373. doi: 10.3324/haematol.2020.272500. Haematologica. 2021. PMID: 33730844 Free PMC article. Clinical Trial.

2

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M. Jabbour E, et al. Among authors: jones r, jones d. Blood. 2006 Aug 15;108(4):1421-3. doi: 10.1182/blood-2006-02-001933. Epub 2006 Apr 6. Blood. 2006. PMID: 16601247 Free article.

3

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.

Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Jabbour E, et al. Among authors: jones d. Blood. 2008 Jul 1;112(1):53-5. doi: 10.1182/blood-2007-11-123950. Epub 2008 Apr 10. Blood. 2008. PMID: 18403620 Free PMC article.

4

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Jabbour E, et al. Among authors: jones d. Blood. 2008 Dec 15;112(13):4839-42. doi: 10.1182/blood-2008-04-149948. Epub 2008 Sep 25. Blood. 2008. PMID: 18818391 Free PMC article.

5

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Cortes JE, et al. Among authors: jones d. J Clin Oncol. 2010 Jan 20;28(3):398-404. doi: 10.1200/JCO.2009.25.4920. Epub 2009 Dec 14. J Clin Oncol. 2010. PMID: 20008620 Free PMC article. Clinical Trial.

6

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.

Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Velev N, et al. Among authors: jones d. Cancer. 2010 Aug 1;116(15):3631-7. doi: 10.1002/cncr.25092. Cancer. 2010. PMID: 20564073 Free article.

7

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED; Cancer Leukemia Group B. Wilson WH, et al. Among authors: jones d. Haematologica. 2012 May;97(5):758-65. doi: 10.3324/haematol.2011.056531. Epub 2011 Dec 1. Haematologica. 2012. PMID: 22133772 Free PMC article. Clinical Trial.

8

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.

Jones D, Woyach JA, Zhao W, Caruthers S, Tu H, Coleman J, Byrd JC, Johnson AJ, Lozanski G. Jones D, et al. Leukemia. 2017 Jul;31(7):1645-1647. doi: 10.1038/leu.2017.110. Epub 2017 Apr 3. Leukemia. 2017. PMID: 28366935 No abstract available.

9

BTK^C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC. Woyach JA, et al. Among authors: jones d, jones ja. J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28418267 Free PMC article. Clinical Trial.

10

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.

Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, Grever MR. Andritsos LA, et al. Among authors: jones d, jones ja. Leuk Lymphoma. 2018 Apr;59(4):1008-1011. doi: 10.1080/10428194.2017.1365853. Epub 2017 Sep 18. Leuk Lymphoma. 2018. PMID: 28918710 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15,096 results

Search Page